Smoking increases choroidal thickness

Article

Cigarette smoking causes a temporary but significant increase in choroidal thickness, according to research conducted at the Department of Ophthalmology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.

Cigarette smoking causes a temporary but significant increase in choroidal thickness, according to research conducted at the Department of Ophthalmology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey and reported in Current Eye Research.

Seventy subjects were included in this study - 40 who had never smoked and 30 who had smoking histories of at least 10 years. Using spectral domain optical coherence tomography, researchers measured choroidal thicknesses at the fovea and at two points 1500 µm nasal and temporal to the fovea. The non-smoking group was measured as a control; the smoking group was measured before they smoked a cigarette, and at 5, 30 and 60 minutes after smoking.

A statistically significant increase in choroidal thickness was observed between 0 and 5 minutes after smoking at all three points of measurement (p

To read an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.